Eli Lilly (LLY)
921.48
+18.46 (2.04%)
NYSE · Last Trade: Apr 22nd, 6:37 PM EDT
Detailed Quote
| Previous Close | 903.02 |
|---|---|
| Open | 906.40 |
| Bid | 918.00 |
| Ask | 921.25 |
| Day's Range | 902.23 - 922.54 |
| 52 Week Range | 623.78 - 1,133.95 |
| Volume | 2,621,665 |
| Market Cap | 881.47B |
| PE Ratio (TTM) | 40.15 |
| EPS (TTM) | 22.9 |
| Dividend & Yield | 6.920 (0.75%) |
| 1 Month Average Volume | 2,834,577 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
Eli Lilly stock trades for more than $900 per share, which may appear expensive upon first glance.
Via The Motley Fool · April 22, 2026
What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a...
Via StockStory · April 21, 2026
Can Eli Lilly cure cancer? Maybe -- with a little help.
Via The Motley Fool · April 21, 2026
Shares of Eli Lilly, Novo Nordisk and Viking Therapeutics fell Tuesday after Amazon announced it would sell weight-loss drugs.
Via Investor's Business Daily · April 21, 2026
ELI LILLY & CO (NYSE:LLY): A High-Quality Dividend Growth Stock for Patient Investorschartmill.com
Via Chartmill · April 20, 2026
Eli Lilly & Co (NYSE:LLY): A Growth Stock Showing Technical Setup for a Potential Breakoutchartmill.com
Via Chartmill · April 18, 2026
Which S&P500 stocks are gapping on Tuesday?chartmill.com
Via Chartmill · April 21, 2026
There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.
Via The Motley Fool · April 21, 2026
After Fifteen Years, Tim Cook Steps Down, Wall Street Steps Back, Oil Steps Upchartmill.com
Via Chartmill · April 21, 2026
Two analysts weighed in positively about the company's future.
Via The Motley Fool · April 20, 2026
Johnson & Johnson, Albertsons, and Procter & Gamble have each raised their dividends, lifting yields to between 2.3% and 4% despite mixed performance in 2025.
Via MarketBeat · April 20, 2026
Eli Lilly's nuclear move signals a shift beyond AI, as industrial giants like Nucor and Dow turn to reactors for reliable, 24/7 power.
Via Benzinga · April 20, 2026
Regulators approved the company's GLP-1 weight loss pill, Foundayo, at the beginning of April.
Via The Motley Fool · April 20, 2026
Eli Lilly said Monday it will spend up to $7 billion to buy privately held Kelonia Therapeutics for its suite of cancer drugs.
Via Investor's Business Daily · April 20, 2026
Eli Lilly currently trades at $926.10 and has been a dream stock for shareholders. It’s returned 386% since April 2021, blowing past the S&P 500’s 70.2% gain...
Via StockStory · April 20, 2026
No need for a time machine to profit from these companies.
Via The Motley Fool · April 19, 2026
Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock.
Via The Motley Fool · April 18, 2026

One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space.
Via The Motley Fool · April 17, 2026
The company's recent dip may be a buying opportunity.
Via The Motley Fool · April 17, 2026
Via MarketBeat · April 17, 2026
Eli Lilly obesity pill logs 1,390 U.S. scripts in first week, trailing Novo's oral Wegovy as competition in weight-loss drugs intensifies.
Via Benzinga · April 17, 2026
Eli Lilly's oral weight-loss drug, Foundayo, nabbed 1,390 prescriptions in its first week on the market, analysts said Friday.
Via Investor's Business Daily · April 17, 2026
The stock could have plenty of room to run from current levels.
Via The Motley Fool · April 17, 2026
These companies boast significant upside potential.
Via The Motley Fool · April 16, 2026
There are other factors to consider before investing in this -- or any other -- healthcare company.
Via The Motley Fool · April 16, 2026